News | Congenital Heart | June 18, 2018

New Research Explores Role of Gene Mutation in Congenital Heart Defects

UNC researchers shed light on how CHD4 gene defects lead to congenital heart malformations

New Research Explores Role of Gene Mutation in Congenital Heart Defects

June 18, 2018 — Heart defects are the most common type of birth defect, and can be caused by mutations in the gene CHD4. Researchers at the University of North Carolina (UNC) School of Medicine have now revealed key molecular details of how CHD4 mutations lead to congenital heart defects.

The team, in their study published in Proceedings of the National Academy of Sciences, found that the CHD4 protein normally works in developing heart muscle cells to repress the production of muscle-filament proteins that are meant to operate in non-heart types of muscle cell. The failure of this repression leads to the development of abnormal, “hybrid” muscle cells that can’t pump blood as efficiently as normal heart cells.

“For patients with congenital heart defects linked to CHD4 mutations, this research helps explain why their hearts don’t work as well as normal, and suggests strategies for therapeutic intervention,” said study senior author Frank Conlon, Ph.D., a professor in the departments of biology and genetics at UNC and a member of the UNC McAllister Heart Institute.

The research was a collaborative effort involving the Conlon Laboratory, the laboratory of Ian Davis, M.D., Ph.D., associate professor in UNC’s division of pediatric hematology-oncology, and the laboratory of Paul Wade, Ph.D., at the National Institute of Environmental Health Sciences.

The team, including first author Caralynn M. Wilczewski, a graduate student in the Conlon Laboratory, began by engineering mice whose developing embryos lack CHD4 just in their heart cells. The embryonic mice developed severe cardiac defects midway through gestation and none was born alive. These results confirmed the necessity for CHD4 in heart development.

CHD4, the protein encoded by the CHD4 gene, normally works as part of a multi-protein “machine” that helps regulate gene activity within the nuclei of cells. The researchers therefore conducted a set of experiments to measure and analyze the changes in developing heart-muscle cell gene activity when CHD4 is absent. They found that the CHD4 protein normally binds directly to DNA in a way that represses the activity of genes that encode non-heart muscle proteins. These proteins help make up the springy fibers (myofibrils) that contract and relax when muscles work.

The team determined that when the CHD4 protein is absent, these other, non-cardiac muscle proteins are inappropriately produced in developing heart muscle cells. They become incorporated into the myofibrils in these cells, forming abnormal, hybrid myofibrils that lack the functional properties of the normal heart.

Wilczewski developed an advanced ultrasound technique and used it to record the activity of the tiny hearts developing in mice — organs that in mid-gestation are only about as large as the period at the end of a sentence.

“We observed that the hearts lacking CHD4 and having these abnormal cardiac myofibrils had severely reduced ventricular contractions, indicating a loss of the ability to pump blood normally,” Wilczewski said.

“These findings indicate that normal cardiac development in mice depends on the repression of non-cardiac myofiber proteins in heart muscle cells, to allow the formation of normal cardiac myofibers capable of sustaining normal heart contractions,” Conlon said.

The findings provide the first clear insight into the mechanism of CHD4-related cardiac defects. They also suggest the possibility that restoring the normal repression of non-cardiac myofiber proteins could prevent heart defects in cases where CHD4 is mutated.

The researchers now plan to investigate the ways in which specific human CHD4 mutations lead to cardiac defects.

In addition, they plan to use the new ultrasound technology developed by Wilczewski in further research. “This technology has broad applications for testing models of congenital heart disease,” Conlon said.

Funding for the study was provided by the National Institutes of Health (R01 HL112618, R01 HL127640, 5T32 HL069768, 1F31 HL136100, ES101965).

For more information: www.pnas.org

 

Reference

Wilczewski C.M., Hepperla A.J., Shimbo T., et al. “CHD4 and the NuRD complex directly control cardiac sarcomere formation.” Proceedings of the National Academy of Sciences, June 11, 2018. https://doi.org/10.1073/pnas.1722219115

 

Related Content

HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init